Serina Therapeutics is located at the HudsonAlpha Institute for Biotechnology
Serina Therapeutics, Inc.
601 Genome Way
Huntsville, Alabama 35806
Phone | 256.327.0566
Email | firstname.lastname@example.org
C. Warren Olanow, M.D., FRCPC is the Henry P. and Georgette Goldschmidt Professor and Chairman Emeritus of the Department of Neurology, and Professor in the Department of Neuroscience at the Mount Sinai School of Medicine in New York City. He is also Visiting Professor in the Department of Neurology at the University of California, San Francisco.
He received his medical degree from the University of Toronto, performed his neurology training at the New York Neurological Institute at Columbia Presbyterian Medical Center at Columbia University, and did post-graduate studies in neuroanatomy at Columbia University. He served on the faculties of McGill University, Duke University, and the University of South Florida prior to joining Mount Sinai.
He is Past President of the Movement Disorder Society, Past President of the International Society of Motor Disturbances and Past Treasurer of the American Neurological Association. He has been named an Honorary Professor at the University of London (Royal Free Hospital), an Honorary Member of the French Neurological Society, an honorary fellow of the Royal College of Physicians of the United Kingdom, the recipient of the Presidential Award from the Movement Disorder Society, and the 2013 recipient of the Movement Disorder Research Award from the American Academy of Neurology.
He serves on the Board of Directors of the National Space Biomedical Research Institute, is a member of the executive committee of the Michael J Fox Foundation Scientific Advisory Board, is the past Chairman of the Scientific Advisory Board of the Bachmann-Strauss Foundation and has served on numerous additional medical and scientific advisory boards. He has served on several editorial boards, and is presently Co-Editor-in-Chief of the journal Movement Disorders.
His clinical and basic science research efforts are directed toward defining more effective therapies for Parkinson’s disease and other neurodegenerative disorders, with a specific interest in strategies that deliver continuous dopaminergic stimulation. Dr. Olanow has authored more than 350 publications, and was ranked #1 in the United States in research citations for Parkinson’s disease during the past quarter century. He has lectured on movement disorders at Universities and Conferences throughout the world.